Primary抗体 Diluent

目录号 GTX28208

实验应用	IHC
产品包装	250 ml (¥2400)

查看所有 Antibody diluent 的产品

说明书
文献引用

View product citations for antibody GTX28208 on CiteAb

产品说明

摘要

Primary antibody diluent (with background reducing component)

产品应用

应用说明

Preparation of Reagent: Bring the diluent to room temperature and mix thoroughly before use. No further preparation is required. Procedure: 1) Pour the diluent in a clean glass container. 2) Add concentrated primary antibody directly in the diluent and mix thoroughly. 3) Diluted antibody is ready to use now and should be stored at 2-8¼ C for further use.

产品属性

形式

Liquid

存放说明

Keep as concentrated solution, aliquot and store at 4ºC.

注意事项

仅供实验室使用。不适用于人类或动物的任何临床，治疗或诊断用途。不适合动物或人类食用。

產品图片

GTX28208 IHC Image

文献引用

Application Reference

Kukida M et al. Front Cardiovasc Med 2023; 10 : 1250234 Manipulation of components of the renin angiotensin system in renal proximal tubules fails to alter atherosclerosis in hypercholesterolemic mice.

Besse HC et al. Cancers (Basel) 2019; 11 (10) Tumor Drug Distribution after Local Drug Delivery by Hyperthermia, In Vivo.

Zhang L et al. Ann Diagn Pathol 2019; 40 : 143-151 The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.

Liu X et al. Ann Diagn Pathol 2018; 38 : 67-70 FOXP3 and CD25 double staining antibody cocktails identify regulatory T cells in different types of tumor tissues using tissue microarrays.

Hoogsteen IJ et al. Int J Radiat Oncol Biol Phys 2012; 84 (3) : 807-14 Expression of EGFR under tumor hypoxia: identification of a subpopulation of tumor cells responsible for aggressiveness and treatment resistance.

显示更多 +

我要回报文献

产品评论

目前没有使用 Primary Antibody Diluent (GTX28208) 的产品评论被收录。快发表第一篇产品评论吧！

我要评论产品

Application Reference

Kukida M et al. Front Cardiovasc Med 2023; 10:1250234 Manipulation of components of the renin angiotensin system in renal proximal tubules fails to alter atherosclerosis in hypercholesterolemic mice.

Besse HC et al. Cancers (Basel) 2019; 11 (10) Tumor Drug Distribution after Local Drug Delivery by Hyperthermia, In Vivo.

Zhang L et al. Ann Diagn Pathol 2019; 40:143-151 The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.

Liu X et al. Ann Diagn Pathol 2018; 38:67-70 FOXP3 and CD25 double staining antibody cocktails identify regulatory T cells in different types of tumor tissues using tissue microarrays.

Hoogsteen IJ et al. Int J Radiat Oncol Biol Phys 2012; 84 (3):807-14 Expression of EGFR under tumor hypoxia: identification of a subpopulation of tumor cells responsible for aggressiveness and treatment resistance.

Nijkamp MM et al. Radiother Oncol 2011; 101 (1):165-70 Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma.

Hoeben BA et al. J Nucl Med 2010; 51 (7):1076-83 PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.

Troost EG et al. J Nucl Med 2010; 51 (5):713-9 Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.

产品包装

报价 (¥)

250 ml

¥ 2400

Qty

Primary抗体 Diluent

目录号 GTX28208

实验应用

摘要

产品应用

应用说明

产品属性

形式

存放说明

注意事项

產品图片

GTX28208 IHC Image

文献引用

Application Reference

产品评论

产品

研究

支持

公司

Follow Us

粤ICP备08007346号-9

© 1998-2022 GeneTex, Inc. 保留所有权利。

所有产品仅供研究使用 - 不应用于诊断或治疗。

	(全国热线) 4006-800-892 / (深圳) 0755-26755892 / (北京) 010-88594029 / (上海) 021-34613729 / (广州) 18024516375 / (香港) +852-69410778
	http://www.neobioscience.com
	genetex@neobioscience.com